Henig Oryan, Kehat Orli, Meijer Suzy E, Chikly Amanda, Weiss-Meilik Ahuva, Egoz Eyal, Ben-Ami Ronen, Paran Yael
Infectious Disease and Epidemiology Department, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel.
Medata AI Center, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
Antibiotics (Basel). 2021 Aug 31;10(9):1056. doi: 10.3390/antibiotics10091056.
During the recent pandemic, the fact that the clinical manifestation of COVID-19 may be indistinguishable from bacterial infection, as well as concerns of bacterial co-infection, have been associated with an increased use of antibiotics. The objective of this study was to assess the effect of targeted antibiotic stewardship programs (ASP) on the use of antibiotics in designated COVID-19 departments and to compare it to the antibiotic use in the equivalent departments in the same periods of 2018 and 2019. Antibiotic consumption was assessed as days of treatment (DOT) per 1000 patient days (PDs). The COVID-19 pandemic was divided into three periods (waves) according to the pandemic dynamics. The proportion of patients who received at least one antibiotic was significantly lower in COVID-19 departments compared to equivalent departments in 2018 and 2019 (Wave 2: 30.2% vs. 45.6% and 44.9%, respectively; Wave 3: 30.5% vs. 47.8% and 50.1%, respectively, < 0.001). The DOT/1000PDs in every COVID-19 wave was lower than during similar periods in 2018 and 2019 (179-282 DOT/1000PDs vs. 452-470 DOT/1000PDs vs. 426-479 DOT/1000PDs, respectively). Moreover, antibiotic consumption decreased over time during the pandemic. In conclusion, a strong ASP is effective in restricting antibiotic consumption, particularly for COVID-19 which is a viral disease that may mimic bacterial sepsis but has a low rate of concurrent bacterial infection.
在最近的疫情大流行期间,2019冠状病毒病(COVID-19)的临床表现可能与细菌感染难以区分这一事实,以及对细菌合并感染的担忧,导致抗生素的使用增加。本研究的目的是评估针对性抗生素管理计划(ASP)对指定COVID-19科室抗生素使用的影响,并将其与2018年和2019年同期同等科室的抗生素使用情况进行比较。抗生素消耗量以每1000患者日(PD)的治疗天数(DOT)来评估。根据疫情动态,将COVID-19大流行分为三个时期(波次)。与2018年和2019年的同等科室相比,COVID-19科室中至少接受过一种抗生素治疗的患者比例显著更低(第二波:分别为30.2% 对45.6% 和44.9%;第三波:分别为30.5% 对47.8% 和50.1%,P<0.001)。COVID-19每个波次的DOT/1000PD均低于2018年和2019年的同期水平(分别为179 - 282 DOT/1000PD对452 - 470 DOT/1000PD对426 - 479 DOT/1000PD)。此外,在大流行期间,抗生素消耗量随时间减少。总之,强有力的ASP在限制抗生素消耗方面是有效的,特别是对于COVID-19这种可能类似细菌性脓毒症但合并细菌感染率较低的病毒性疾病。